Brain accumulation of soluble oligomers of the amyloid-b peptide (AbOs) is increasingly considered a key early event in the pathogenesis of Alzheimer's disease (AD). A variety of AbO species have been identified, both in vitro and in vivo, ranging from dimers to 24mers and higher order oligomers. However, there is no consensus in the literature regarding which AbO species are most germane to AD pathogenesis. Antibodies capable of specifically recognizing defined subpopulations of AbOs would be a valuable asset in the identification, isolation, and characterization of AD-relevant AbO species. Here, we report the characterization of a human single chain antibody fragment (scFv) denoted NUsc1, one of a number of scFvs we have identified that stringently distinguish AbOs from both monomeric and fibrillar Ab. NUsc1 readily detected AbOs previously bound to dendrites in cultured hippocampal neurons. In addition, NUsc1 blocked AbO binding and reduced AbO-induced neuronal oxidative stress and tau hyperphosphorylation in cultured neurons. NUsc1 further distinguished brain extracts from AD-transgenic mice from wild type (WT) mice, and detected endogenous AbOs in fixed AD brain tissue and AD brain extracts. Biochemical analyses indicated that NUsc1 targets a subpopulation of AbOs with apparent molecular mass greater than 50 kDa. Results indicate that NUsc1 targets a particular AbO species relevant to AD pathogenesis, and suggest that NUsc1 may constitute an effective tool for AD diagnostics and therapeutics.
Evidence obtained during the past two decades implicates the accumulation of soluble Ab oligomers (AbOs) in the brain, rather than fibrillar Ab deposits in plaques, as the primary synaptotoxic form of Ab (Ferreira and Klein 2011; Hayden and Teplow 2013; Klein 2013; Selkoe and Hardy 2016) . Although the toxicity of AbOs was identified almost 20 years ago (Lambert et al. 1998) , the identity of the most Alzheimer's Disease-relevant AbO species remains unknown (Benilova et al. 2012; Viola and Klein 2015) . Dimers, trimers, and other low molecular weight AbOs have been implicated in AD pathogenesis (Cleary et al. 2005; Walsh et al. 2005; Li et al. 2011; Figueiredo et al. 2013) . Others have proposed a primary pathogenic role for higher molecular weight soluble AbOs, that is, greater than 50 kDa (Gong et al. 2003 ; Lesne et al. 2006; Velasco et al. 2012; Mc Donald et al. 2015; Savioz et al. 2016) .
Because of the non-abundance of AbOs in AD brain as well as their instability and molecular heterogeneity (Teplow 2013) , antibodies have played a prominent role in the identification and characterization of AD-relevant AbOs. A number of antiAb conformational-specific antibodies have been developed (Goure et al. 2014; Murakami 2014; Viola and Klein 2015) and utilized to characterize distinct AbO conformations, including annular protofibrillar oligomers (Kayed et al. 2009 ), amylospheroids (Noguchi et al. 2009; Matsumura et al. 2011) , and globulomers (Hillen et al. 2010) , among others. Notably, it is now recognized that distinct AbO conformations have differential neurotoxicity (Figueiredo et al. 2013) . In line with this notion, Ashe and colleagues have classified AbOs isolated from the brains of AD mice as 'Type I' and 'Type II' AbOs , with Type I AbOs being involved in cognitive impairment. This type of conformational classification is in harmony with our previous demonstration that AbOs of molecular mass greater than 50 kDa are AD-relevant, while those less than 50 kDa are not (Lacor et al. 2007; Velasco et al. 2012; Sebollela et al. 2014) .
In addition to full-length IgG antibodies, conformationspecific antibody fragments against Ab have been developed. Single chain variable fragment (scFv) phage display technology allows screening of hundreds of scFvs for the ability to bind an antigen of interest with relatively little effort, in a process termed biopanning (Azzazy and Highsmith 2002; Ahmad et al. 2012 ). Solomon and colleagues first demonstrated that a scFv produced by phage display retained the ability to block Ab fibril formation, similar to its parent IgM (Frenkel et al. 2000) . The same group subsequently demonstrated that filamentous phage could be used as a vector to deliver scFvs to Ab plaques in the brain when introduced intranasally in mice Solomon and Frenkel 2002) . Since then, many groups have developed antiAb scFvs (Liu et al. 2004; Solorzano-Vargas et al. 2008; Medecigo et al. 2010; Wang et al. 2016) . Conformationspecific anti-Ab scFvs in the literature include those specific for AbOs (Zameer et al. 2008; Meli et al. 2009; Wang et al. 2009 ), AbOs and protofibrils (Zhang et al. 2015) , and AbO subpopulations (Kasturirangan et al. 2012 (Kasturirangan et al. , 2013 .
Here, we present the characterization of a human scFv antibody specific for a particular subspecies of AD-relevant AbOs. This scFv, termed NUsc1, is one of a set of scFvs we isolated by biopanning against AbOs, which stringently distinguish AbOs from both monomeric and fibrillar Ab. The relevance to AD of the AbO species targeted by NUsc1 is demonstrated by the finding that NUsc1 distinguishes AD brains from non-demented controls and AD mouse brains from WT mice. Furthermore, NUsc1 reduced neuronal oxidative stress and tau hyperphosphorylation in hippocampal cultures exposed to AbOs. Results further indicated that NUsc1 selectively binds a small subset of oligomer species in the ensemble of AbOs.
Materials and methods

Screening and isolation of anti-AbOs scFvs
Anti-AbO scFv selection was performed as previously reported (Velasco et al. 2012) . Briefly, AbOs were prepared using Ab1-42 (American Peptide, Sunnyvale, CA, USA) as in (Chromy et al. 2003) . When separated by HPLC-SEC, AbO preparations displayed a typical 2-peak profile comprising low and high molecular mass oligomers (Sebollela et al. 2014) . Freshly prepared AbOs were immobilized in immunotubes (Nunc) at 10 lg/mL (mass refers to Ab 1-42 monomer) overnight at 37°C. Clones with high affinity for AbOs were selected from the Tomlinson I + J human scFv library (Nissim et al. 1994 ) by phage display after four rounds of panning. Selected E.coli TG1 clones were used to produce phage displaying scFvs after co-infection with helper phage KM13. Supernatants containing phage-bound scFvs were directly used or partially purified by polyethylene glycol (MW 6000)/NaCl precipitation (Barbas et al. 2004 ).
Production of phage-free NUsc1
Phage-free NUsc1 was produced by expression in the HB2151 E.coli strain with IPTG (Isopropyl b-D-1-thiogalactopyranoside) induction essentially as described in Barbas et al. (2004) . Phage-free NUsc1 was purified from both the supernatant and cell lysate of the HB2151 cells using a Protein A affinity column (Nissim et al. 1994) . The concentration of soluble protein in the supernatant was determined by UV absorption at 280 nm, assuming that the A 280 of a 0.7 mg/mL solution is equal to 1 (Griffiths et al. 1993) . Purified NUsc1 was stored in phosphate-buffered saline (PBS) (Dulbecco's PBS without calcium or magnesium; Corning), pH 7.4 at À80°C. After analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and SEC (size-exclusion chromatography), the following were added to NUsc1 for cryoprotection: 15% glycerol, 0.1% casein, and 1 mM PMSF (phenylmethane sulfonyl fluoride) (Brichta et al. 2003) .
SDS-PAGE and SEC analysis of phage-free NUsc1
Purified phage-free NUsc1 (1 lg) was resolved on a 4-15% TrisGlycine gel (Bio-Rad Laboratories, Hercules, CA, USA). Coomassie dye (Imperial Protein Stain, Thermo Fisher Scientific) was used for total protein detection. Alternatively, protein was transferred to nitrocellulose, which was probed by anti-c-myc (1 lg/mL, clone 9E10 from ATCC, Manassas, VA, USA) followed by anti-mouse IgG-horseradish peroxidase (HRP) (1 : 10 000; Jackson ImmunoResearch Laboratories), or anti-6xHis-HRP (1 : 5000; Pierce, Rockford, IL, USA). FPLC-SEC was conducted at 4°C on a Superdex 200 Increase SEC column (GE Life Sciences, Uppsala, Sweden), calibrated with seven protein standards ranging from 6.5-669 kDa, with PBS (150 mM NaCl, 1 mM KH 2 PO 4 , 5.6 mM Na 2 HPO 4 , pH 7.4) as the mobile phase. Blue dextran was used to determine the column void volume.
Dot immunoblotting with phage-free NUsc1
AbOs were titrated in PBS (150 mM NaCl, 1 mM KH 2 PO 4 , 5.6 mM Na 2 HPO 4 , pH 7.4) and blotted onto nitrocellulose membrane. Phage-free NUsc1 or NU2 ) primary antibodies, both at 8 lg/mL, were incubated overnight at 4°C. HRPlinked antibodies against the 6xHis tag (for NUsc1 detection; Proteintech Group Inc) or mouse-IgG (for NU2 detection; GE Lifesciences) were used for 1 h at 24°C. Chemiluminescent signal was developed using SuperSignal West Femto Maximum Sensitivity Substrate (ThermoScientific, Rockford, IL, USA).
ELISA with phage-free NUsc1
AbOs (100 lL at 200 nM in PBS per well, or variable concentrations, where indicated) were incubated in high-adsorption 96-well plates (MaxiSorp, ThermoFisher Scientific, Rochester, NY, USA) overnight at 4°C with gentle orbital agitation. The next day, the plate was washed/blocked three times with 3% bovine serum albumin (BSA)/ PBS (2 9 10 min; 1 9 30 min). NUsc1 was added at 16 lg/mL (or variable concentrations, where indicated) in 3% BSA/PBS and incubated for 2 h at 24°C. The plate was washed three times with 0.1% Tween 20/PBS using a plate washer (BioTek). HRP-conjugated antibody against 6xHis diluted 1 : 1000 in 3% BSA/PBS was added for 45 min at 24°C. The plate was washed again three times with 0.1% Tween 20/PBS. Colorimetric signal was developed with TMB (tetramethylbenzidine; Sigma, St Louis, MO, USA). Reaction was stopped by addition of 10% phosphoric acid. Absorbance at 405 nm was measured on BioTek Synergy plate reader.
Immunoprecipitation of AbOs with NUsc1
Magnetic beads for His-tag isolation (Dynabeads; Invitrogen) were functionalized with phage-free NUsc1 following manufacturer's instructions. Functionalization was confirmed by reactivity to HRPconjugated anti-c-myc (9E10; RRID: AB_627268) as measured by colorimetric conversion of peroxidase substrate TMB (Sigma) (not shown). For immunoprecipitation, freshly prepared AbOs were fractionated by centrifugal filtration using 50 kDa MWCO membranes (Microcon YM-50; Amicon, Bedford, MA, USA) as in (Velasco et al. 2012) . The resulting filtrate (1.2 lg) or retentate was diluted in 0.1 % BSA/PBS and incubated with NUsc1-functionalized or non-functionalized beads (10 lL) for 16 h at 4°C. Next, beads were washed twice with 0.1 % BSA/PBS, resuspended in denaturing SDS-PAGE buffer, and loaded onto a 10-20% Tris-Tricine gel (Life Technologies, Grand Island, NY, USA). Total protein was detected on the gel by silver staining (SilverXpress, Invitrogen).
Oligomerization of tau
Oligomerization of tau was performed as described (Ward et al. 2013) . Briefly, the 2N4R isoform of human recombinant tau (rPeptide) was incubated at 4 lM with 75 lM of arachidonic acid in aggregation buffer (10 mM HEPES, pH 7.6, 100 mM NaCl, 0.1 mM EGTA, 5 mM dithiothreitol) for 6 h at 24°C with no agitation. To stop the reaction, the buffer was exchanged to PBS via three rounds of buffer exchange in a 10 kDa MWCO centrifugal filter (Millipore Ultrafree-MC). The sample was stored at À80°C until analysis. Successful oligomerization was confirmed by western immunoblotting ( Figure S1 ). For this, samples were diluted in Laemmli sample buffer without addition of a reducing agent or sample boiling; 10 ng of tau was loaded per well of a 4-20% Tris-Glycine sodium dodecyl sulfate-polyacrylamide gel (Novex, ThermoFisher Scientific). After transfer, tau was detected using the DA31 total tau antibody (Acker et al. 2013) diluted to 1.5 lg/mL.
AbO-Tau competition sandwich ELISA AbOs were stabilized by the chemical cross-linker DFDNB (1,5-Difluoro-2,4-dinitrobenzene; Sigma) by incubating with a fivefold molar excess of DFDNB over Ab peptide for 10 min at 24°C (Grimm et al. 2007) . The cross-linking reaction was quenched by incubation with dithiothreitol at a 1 : 1 molar ratio with DFDNB for 30 min at 24°C. For ELISA, high-adsorption 96-well plates (MaxiSorp, ThermoFisher Scientific) were coated by overnight stationary incubation with 100 lL of monoclonal anti-AbO antibody NU2 ) at 1.0 lg/mL in PBS at 4°C. The next day, the plate was blocked with 200 lL of 3% BSA/PBS (2 9 10 min, 1 9 30 min) without agitation. DFDNB-AbOs (100 lL ) was added at 16-1000 nM for AbO dose-response, or 125 nM for tau competition, diluted in 3% BSA/PBS and incubated 2 h at 24°C, with no agitation. Wells were then washed 39 with 0.1% Tween-20/PBS and incubated with phage-free NUsc1 at 16 lg/mL either without tau (AbO dose-response) or with 25-800 nM tau (tau competition) in 3% non-fat milk/PBS for 2 h at 24°C. Bound antibody was detected by incubation with HRPconjugated anti-6xHis (Proteintech, Rosemont, IL, USA). Plates were developed using TMB (Sigma). Absorbance at 405 nm was measured on a BioTek Synergy plate reader.
Primary neuronal cultures and immunocytochemistry
Hippocampal neurons from rat embryos were cultured according to Brewer et al. (1993) . Briefly, a pregnant SpragueÀDawley rat (gestation day 18; Charles River International, Inc., RGD_737891) was anesthetized, decapitated, embryos removed, and the embryonic hippocampi were dissected and dissociated. Dissociated cells were plated and maintained in Neurobasal medium supplemented with B27 (Invitrogen) for at least 18 days before treatment. Animals were handled in accordance with national guidelines laid down by the NIH regarding care and use of animals for experimental procedures. After maturation of the cultures, cells were exposed to AbOs (250 nM) for 30 min at 37°C, washed twice with medium, and fixed using 4% formaldehyde/4% sucrose. Cells were blocked with 5% normal goat serum/PBS, and incubated with indicated primary antibodies followed by Alexa Fluor â -conjugated secondary antibodies (Life Technologies) at 1 : 500-1 : 1000. Coverslips were mounted with ProLong Gold containing DAPI (Life Technologies), air-dried, and imaged using a Nikon TE-2000 inverted microscope.
Neuroprotection by NUsc1
Generation of reactive oxygen species (ROS) was evaluated in live neurons as described previously Saraiva et al. 2010; Figueiredo et al. 2013 ) using the fluorescent probe CM-H2DCFDA (Invitrogen). Mature hippocampal cultures were incubated for 3 h at 37°C with vehicle or 500 nM AbOs in the presence of NUsc1, as indicated. In the last 40 min of exposure to AbOs, cells were incubated with 2 lM CM-H2DCFDA at 37°C. Cells were then rinsed three times with warm PBS and imaged. Quantitative analysis of DCF fluorescence data was performed using Image J (NIH), as previously described (Figueiredo et al. 2013) . The ability of NUsc1 to prevent AbO-induced tau hyperphosphorylation was also evaluated. Primary hippocampal cultures were exposed to AbOs (500 nM) in the absence or presence of phage-free NUsc1 (25 lg/mL), or to phage-free NUsc1 alone, for 5 h. Prior to addition to cell culture, AbOs and NUsc1, alone or mixed, were incubated in Neurobasal medium for 30 min at 37°C. After treatment, cells were fixed with 1.85 % formaldehyde for 10 min followed by 3.7 % formaldehyde for 10 min. Cells were washed 3 9 5 min in PBS, then blocked with 10% normal goat serum/ PBS for 1 h at 24°C. Cells were then incubated with anti-pTau [T205] (Sigma; diluted 1 : 500 in 10% normal goat serum/PBS) overnight at 4°C, followed by incubation with the appropriate Alexa Fluor-linked secondary antibodies (1 : 2000 in 1% normal goat serum/PBS) for at least 3 h. To visualize nuclei, Hoescht (Invitrogen) was added at 2 lg/mL immediately prior to imaging at 409 on the ImageXpress High Content Imaging Robotic Platform (Molecular Devices, Sunnyvale, CA, USA); 25-100 images were collected per condition. Image analysis was performed in ImageJ (NIH). To quantify tau phosphorylation, corrected total cell fluorescence was normalized by cell count, determined by Hoescht staining of nuclei.
Brain extracts
A procedure based on Gong et al. (2003) was utilized to prepare extracts from the cortices of 5xFAD transgenic mice (Oakley et al. 2006) , as well as from the frontal cortex of AD or age-matched cognitively normal human subjects. 5xFAD heterozygous males were purchased from MMRRC (RRID: MMRRC_034840-JAX) and bred in-house on a C57BL/6J background (approved IACUC protocol # 2013-3508 ) and centrifuged at 10 000 g for 10 min at 4°C. The pellet was re-homogenized in 10 volumes of the same medium and centrifuged again. In the case of mouse brains, medium was supplemented with 0.5 % Triton X-100. Supernatants were combined and centrifuged at 100 000 g for 1 h at 4°C to remove insoluble material, including fibrils. Protein concentration in the AbO-rich supernatant fractions was determined using the 660 nm protein assay reagent (Pierce).
Sandwich ELISA for brain extracts using phage-bound NUsc1 High-adsorption 96-well plates (MaxiSorp, ThermoFisher Scientific) were coated by overnight incubation with 100 lL of monoclonal anti-pan Ab antibody (6E10, Covance, RRID AB_2564653) at 1.0 lg/mL in PBS at 4°C. The next day, the plate was blocked with 200 lL of 2% milk/PBS. Brain extracts were added at 0.5 mg/mL (total protein) diluted in 2% milk/PBS and incubated overnight at 4°C. Wells were then washed with 0.05% Tween-20/PBS and incubated with phage-bound NUsc1 at 1 : 100 dilution in 2 % milk/PBS for 2 h at 24°C. Bound antibody was detected by incubation with HRP-conjugated antiphage M13 (GE). Plates were developed using TMB (Sigma).
Immunohistochemistry APP (Amyloid precursor protein)/PS1 mice (RRID: MMRRC_ 034832-JAX) were purchased from Jackson Labs and were bred in-house on a C57BL/6J background (approved CEUA/UFRJ protocol #01200.001568/2013-87). Mice were transcardially perfused with saline followed by fresh 4% formaldehyde. Brains were removed and fixed for 24 h in the same solution, and then embedded in paraffin after dehydration and diaphanization. Sections (10 lm) were immersed in xylene for 10 min, rehydrated, and incubated with 3% H 2 O 2 in methanol. After antigen reactivation by treatment with 0.01 M citrate buffer (40 min at 95°C) and blocking, sections were incubated with phage-bound NUsc1 (1 : 1 in blocking buffer) overnight at 4°C. Slides were incubated with biotinylated secondary antibody for 2 h and incubated with streptavidin-biotin-peroxidase for 30 min. Finally, reactivity was developed using DAB solution (0.06% DAB (3,3 0 -diaminobenzidine) in PBS containing 2% dimethylsulfoxide and 0.018% H 2 O 2 ) for 1-5 min. Reaction was stopped by immersion of slides in distilled water. Counter-staining was performed with Harris hematoxylin. Alternatively, immunofluorescence was carried out. In this case, slices were blocked with 3% BSA and incubated for 2 h at 24°C with Alexa 555-conjugated anti-mouse IgG (1 : 2000). Slices were mounted on coverslips using Prolong Gold Antifade (Invitrogen) and imaged on a Zeiss Axio Observer Z1 Microscope equipped with an Apotome module. Postmortem human brain tissue was also used. In this case, autopsied brain sections from AD patients and cognitively normal subjects (Northwestern University CNADC) were immunolabeled as described in Lacor et al. (2004) . Briefly, tissue was fixed in 4% paraformaldehyde and transferred to a 10-40% sucrose gradient. Free-floating 40-lm-thick serial sections were obtained from frontal cortex. Sections were rinsed with Tris-buffered saline (20 mM Tris, pH 7.6, 0.2 M NaCl), blocked with 5% horse serum in Tris-buffered saline with 0.5% Triton X-100 and 1% milk (40 min at 24°C), and were incubated with phage-bound NUsc1 (1 : 1), NU1 (1.5 lg/mL; Lambert et al. 2007 ) overnight at 4°C. Sections were then incubated for 90 min at 24°C with secondary antibodies anti-M13 (GE; 1 : 250 dilution) and Alexa Fluor antimouse or anti-rabbit IgG (1 : 500 dilution). Images were acquired on a Nikon T3000 microscope. Sections were counter-stained with DAPI. Control sections with primary or secondary antibodies omitted showed no fluorescent signal (not shown).
Statistical analysis
Statistical significance in the difference between population means was determined by the Student's t-test or a two-way ANOVA followed by Dunnett's test, where indicated. A p-value less than 0.05 was considered statistically significant in all cases.
Results
Screening and characterization of anti-Ab oligomer scFvs Selection of anti-Ab oligomer (AbO) scFvs was performed by panning a phage display library of human IgG-derived scFvs (Nissim et al. 1994 ) against immobilized AbOs. A set of 11 scFvs (henceforth referred to as NUscs) thus isolated was found to efficiently distinguish oligomers from both monomeric and fibrillar Ab (Fig. 1a) . Ab1-40 was used to prepare monomeric Ab since it is known to self-assemble into oligomers/fibrils at a much slower rate than Ab1-42 (e.g., Vandersteen et al. 2012 ) and would remain predominately monomeric under our experimental conditions. Among the selected NUscs, in this study, we have focused on NUsc1, which we previously reported to target a small subset of synapse-binding AbOs that are > 50 kDa in molecular mass (Velasco et al. 2012) .
To investigate further the specificity of NUsc1, we asked whether it also reacted with toxic oligomers formed from non-Ab proteins, as previously demonstrated for other antioligomer antibodies such as A11 (Kayed et al. 2003) . To this end, neurotoxic lysozyme oligomers were prepared as previously described (Vieira et al. 2007 ) and the immunoreactivity of phage-bound NUsc1 toward oligomers from Ab or lysozyme was compared by ELISA. At equal concentrations of Ab or lysozyme oligomers, NUsc1 detection of AbOs was 75-fold stronger than detection of lysozyme oligomers (Fig. 1b) . As expected, measurements with the A11 antibody showed immunoreactivity to both AbOs and lysozyme oligomers, but no binding to lysozyme monomers. The reactivity of NUsc1 toward oligomers from the neuronal protein tau was further investigated using a competition ELISA sandwich assay against cross-linked AbOs. Titration of AbOs in the absence of tau revealed a dose-response curve with an EC 50 = 94 nM Ab for NUsc1 in this assay (Fig. 1c) . When the AbO concentration was held constant at 125 nM, addition of increasing concentrations of tau oligomers (TauOs) did not lead to a dose-dependent decrease in signal, indicating no significant binding of TauOs to NUsc1. A tendency to decrease in signal was observed only at the highest concentration of TauOs tested (800 nM). Control measurements showed that the capture antibody, NU2, did not bind monomeric tau or tau oligomers (data not shown).
Phage-free NUsc1 retains its structure and AbO-binding activity: NUsc1 was expressed free of bacteriophage using the HB2151 E. coli strain. Expression of intact NUsc1 was confirmed by SDS-PAGE ( Figure S1a ), which revealed a major protein band migrating between the 25 and 34 kDa standards, in agreement with the expected molecular mass of 28 kDa for human scFvs. Expression of phage-free NUsc1 was further confirmed by immunoblotting using antibodies against the c-myc and 6xHis affinity tags included in the construct ( Figure S1b) .
Because the stability of scFvs is reported to be a common problem (Worn and Pluckthun 2001) , the aggregation state of phage-free NUsc1 was analyzed by size exclusion chromatography (SEC). Figure 2a shows that phage-free NUsc1 elutes as a single peak corresponding to a molecular mass of 24 kDa in the calibrated column, in agreement with the expected molecular mass for the scFv.
The AbO-binding capacity of phage-free NUsc1 was analyzed next. Dot immunoblotting revealed that phage-free NUsc1 retained AbO-binding activity (Fig. 2b) . Compared to the full-length anti-AbO monoclonal antibody NU2 , however, NUsc1 yielded a weaker signal and a higher detection limit. Analysis of AbO-binding activity by ELISA showed dose-dependent signals as a function of the concentrations of both AbOs (Fig. 2c) and phage-free NUsc1 (Fig. 2d) . Fitting the data with a fourparameter non-linear binding equation yielded an EC 50 of 20 pmol AbOs (Fig. 2c) and 123 lg/mL NUsc1 (Fig. 2d) . Each of the assays presented in Fig. 2 were conducted with phagefree NUsc1 that had been stored at 4°C for up to 1 month. This indicates that phage-free NUsc1 is stable during at least this time frame.
NUsc1 detects AbOs bound to neurons in culture
We next examined whether NUsc1 targets neuron-bound AbOs. Indeed, phage-bound NUsc1 labeled AbOs that had been previously added and were bound to cultured hippocampal neurons (Fig. 3, right) . The punctate dendritic labeling pattern obtained with NUsc1 closely resembles the pattern obtained using our AbO-selective polyclonal or monoclonal antibodies (Lambert et al. 2001 and indicates targeting of AbOs bound to synapses. No dendritic binding was detected by NUsc1 in vehicle-exposed cultures (Fig. 3, left) . A combination of phage-bound NUsc1-based immunofluorescence and differential interference contrast microscopy clearly showed NUsc1 targeting of AbOs bound to dendrites (Fig. 3d) . By contrast, no AbO-dependent labeling was observed in cultures labeled with phage-bound NUsc16, an scFv that shows no interaction with AbOs by ELISA (data not shown).
NUsc1 detects AbOs in Tg mouse brain
Next, we investigated the capacity of NUsc1 to recognize AbOs in brain extracts from two distinct mouse models of AD. Phage-bound NUsc1 reacted with Ab oligomers in fixed brain sections from APP/PS1 mice (Jankowsky et al. 2004) (Fig. 4a) , as detected by both immunofluorescence (left) and DAB staining (right). Little-to-no NUsc1 signal was observed in WT mouse brains (Fig. 4a) . Phage-bound NUsc1 also readily discriminated brain extracts from 5xFAD (Oakley et al. 2006) or WT mice in an ELISA assay, similar to the polyclonal anti-AbO IgG m70 (Lambert et al. 2001) (Fig. 4b) .
NUsc1 detects AbOs in AD brain
The capacity of NUsc1 to detect AbOs in AD brain was investigated. Donors were male and diagnosed with either probable or definitive AD based on the CERAD (Consortium to Establish a Registry for Alzheimer's Disease) score. The ability of NUsc1 to detect AbOs in fixed slices from AD or control brains was analyzed by immunohistochemistry. Strong AD-dependent reactivity of phage-bound NUsc1 was observed, with intensity of labeling increasing with patient diagnosis from probable to definitive AD (Fig 5a-c) . In addition, NUsc1 discriminated between brain extracts from age-matched, non-demented controls and the majority of AD subjects in an ELISA assay (Fig. 5d) . The lack of significant interaction of NUsc1 with Tau oligomers (Fig. 1c) indicates that the labeling seen in AD brain, where Tau aggregates are expected to be present, is indeed derived from Ab aggregates.
Neuroprotection by NUsc1
Based on its capacity to bind AbOs in Tg mouse and AD brains, as well as in vitro, the ability of NUsc1 to block AbOelicited neurotoxicity was examined. Neuroprotection by NUsc1 was tested by analyzing its capacity to block or reduce AbO-induced toxic events in rat hippocampal neurons, namely excessive ROS accumulation ) and tau hyperphosphorylation (De Felice et al. 2008) . While cultures challenged with AbOs presented a robust increase in ROS levels compared to vehicle-treated cultures ( Fig. 6a and b) , pre-incubation with phage-bound NUsc1 significantly reduced AbO-induced ROS accumulation (Fig. 6c) . Control measurements showed lack of oxidative stress induced by NUsc1 itself (Fig. 6d) . Similar results were obtained by measuring AbO-induced tau hyperphosphorylation. Hippocampal cultures challenged with AbOs presented a twofold increase in levels of phosphorylated tau (p-tau) (Fig. 7) . Pre-incubation with phage-free NUsc1 completely blocked AbO-induced p-tau. Importantly, post-treatment total cell counting revealed that phage-free NUsc1 itself did not instigate cell death in this assay (data not shown). These results strongly support the notion that NUsc1 neutralizes toxic AbOs in solution.
NUsc1 targets a subset of AbOs Finally, to identify the AbO species detected by NUsc1, AbOs were fractionated by SEC and fractions were probed for NUsc1 immunoreactivity by dot immunoblotting. NUsc1 predominantly reacted with high molecular weight AbOs (above 60 kDa; Fig. 8a ). Interestingly, specific detection of a subpopulation of AbOs with an apparent molecular mass of 30 kDa (corresponding to a single eluted fraction at 2.3 mL) was also evident. Presence of low molecular weight oligomers (showing as a robust peak centered at an elution volume of~2.6 mL) in the AbO preparation was confirmed by NU1 detection. Low molecular weight oligomers reacted weakly with NUsc1.
The AbO size-dependence of NUsc1 immunoreactivity was further evaluated in an immunoprecipitation assay using purified, phage-free NUsc1-functionalized magnetic beads, followed by SDS-PAGE analysis (Fig. 8b) . Functionalization of the beads with NUsc1 was confirmed by the presence of a~30 kDa band, similar to the NUsc1 standard. Note that no 30 kDa band was present in beads not functionalized with NUsc1. Before incubation with NUsc1-functionalized beads, AbOs were fractionated by centrifugal filtration through a 50 kDa MWCO membrane. AbOs in the resulting filtrate (F; ELISA sandwich assays were carried out using 6E10 as capture antibody and phage-bound NUsc1 as the detection antibody. Bars represent means AE SEM of results from extracts from at least three mice in each group. Difference between WT and 5xFAD mice extracts was statistically significant (p-value < 0.05, Student's t-test) and larger than the difference obtained using polyclonal anti-AbO IgG m70.
< 50 kDa species) or retentate (R; > 50 kDa) were analyzed by SDS-PAGE followed by silver staining (Fig. 8b) . Bands corresponding to Ab, identified by comparison with a synthetic AbO standard (shown in the right-hand side of the gel as 3-4 bands ranging from < 10 to~20 kDa) were only detected in the retentate, substantiating the previous observation that NUsc1 preferentially targets AbOs larger than 50 kDa (Velasco et al. 2012) . Importantly, Abassociated bands were not present in the filtrate, indicating a lack of interaction of NUsc1 with low molecular weight oligomers (< 50 kDa), in agreement with the SEC data in Fig. 8a and previously published work (Velasco et al. 2012 ).
Discussion
In this study, multiple human scFvs, termed NUscs, have been identified that effectively distinguish oligomers of the Ab 1-42 peptide (AbOs) from the less toxic forms of Ab, monomers and fibrils. One of those NUscs, NUsc1, was specific for an epitope present in Ab oligomers but not common to generic amyloid oligomers, such as oligomers formed from lysozyme or Tau. We further demonstrated that, in addition to the phage-bound form, Nusc1 can be expressed as a stable, functional scFv devoid of the bacteriophage vector. NUsc1 was shown to target AbOs in AD and AD model systems, and to prevent the neurotoxicity of AbOs to hippocampal neurons. Interestingly, NUsc1 appears specific for a small subpopulation of toxic AbOs. The current identification of 11 Ab conformation-specific scFvs represents an extension of our previous work with Ab conformation-specific scFvs (Wang et al. 2009; Velasco et al. 2012 ) and full-length IgGs ). Other groups have developed Ab conformation-specific scFvs (Meli et al. 2009 (Meli et al. , 2014 Wang et al. 2016 ). Solomon and colleagues were determined using the ROS-sensitive probe DCFDA, as described . (e) Averaged integrated fluorescence determined from two experiments in triplicate. *p-value < 0.05 (two-way ANOVA followed by Dunnett's test).
presented the first example with scFvs specific for Ab fibrils (Frenkel et al. 2000) . Those scFvs, expressed by phage display, were able to engage Ab plaques in the brains of mice when introduced through intranasal injection Solomon and Frenkel 2002; Solomon 2008) . In another notable example, Sierks and colleagues presented multiple scFvs targeting variants of AbOs that are differentially expressed in AD brain, CSF and serum (Zameer et al. 2008; Kasturirangan et al. 2012 Kasturirangan et al. , 2013 Williams et al. 2016) . It is becoming increasingly apparent that, for greatest efficacy, Ab-directed immunotherapies must target only the most toxic Ab species, so as to prevent off-target engagement of the antibodies and/or undesirable side effects. This is evident from reports showing that Ab immunotherapies employing antibodies with significant affinities for less toxic Ab species, including monomers and fibrils, consistently exhibit amyloid- NUsc1 blocks AbO-induced tau hyperphosphorylation in hippocampal neurons. Cultures were exposed to either vehicle, 500 nM AbOs, or 500 nM AbOs + 25 lg/mL NUsc1 for 5 h. Tau phosphorylation levels were evaluated using an antibody against tau phosphorylated at residue T205. Signal was quantified by pixel area above an intensity threshold and normalized to cell number. Error bar represents standard error of the mean (n = 25 images per group covering 354 9 354 lm). *p-value < 0.005 (Student's t-test). Scale bar = 25 lm. filtration using a 50 kDa MWCO filter and subjected to immunoprecipitation using phage-free NUsc1-functionalized magnetic beads. Filtrate (F < 50 kDa) or retentate (R > 50 kDa) were incubated with NUsc1-functionalized or non-functionalized (control) magnetic beads. Presence of Ab bound to beads was analyzed by SDS-PAGE followed by silver staining. Control lanes containing either purified NUsc1 or unfractionated AbOs ('standards') were included to facilitate identification of individual bands.
related imaging abnormalities (vasogenic edema and microhemorrhages) (Farlow and Brosch 2013; Goure et al. 2014; Sevigny et al. 2016) . The specificity of NUsc1 for an epitope specific to oligomers of Ab, and not general amyloid oligomers, is significant in that it increases its utility for AD-related studies. Other antibodies have been shown to target an epitope shared by oligomers formed from different amyloid proteins, such as the A11 antibody developed by Glabe and colleagues (Kayed et al. 2003) . In addition to AbOs, A11 is known to detect soluble oligomers implicated in multiple diseases, including a-synuclein (Parkinson's disease), islet amyloid polypeptide (type II diabetes), polyglutamine (Huntington's disease), and the prion protein (spongiform encephalopathies). In this study, we found that NUsc1 does not bind significantly to oligomers from either lysozyme or Tau. These findings are significant for the following reasons. First, in the case of lysozyme, although not a mammalian neural protein, soluble oligomers formed in vitro are well characterized, measuring about 10 nm, thus somewhat larger than high molecular mass AbOs (~3.5 nm; Sebollela et al. 2014) and are neurotoxic (Vieira et al. 2007) . Secondly, tau oligomers are relevant because of their increasingly recognized role in AD pathology (e.g., Patterson et al. 2011) . Along with the observation that the NUsc1 binding pattern to both AbO-treated neurons (Fig. 3) and AD human tissue (Fig. 5) is mostly peri-neuronal and closely resembles the patterns obtained using other anti-AbO IgGs such as NU4 (Lacor et al. 2007; Lambert et al. 2007) , our findings lead us to conclude that NUsc1 preferentially targets AbOs. While pan-amyloid antibodies have great utility in studying common pathogenic mechanisms in the corresponding amyloid diseases, they cannot be useful in distinguishing between specific neurodegenerative diseases.
Here, we show that NUsc1 can be expressed as a stable, functional scFv antibody free of its bacteriophage vector. Analysis by SEC showed phage-free NUsc1 to be monodisperse. Its ability to bind AbOs was confirmed in doseresponse dot immunoblotting and ELISA assays. This binding activity was retained for at least 1 month of storage at 4°C. The stability of phage-free NUsc1 is significant as scFvs are known to be prone to aggregation or cleavage at the flexible linker connecting the variable domains (Frenkel et al. 2000; Worn and Pluckthun 2001; Rivera-Hernandez et al. 2013; Cheng et al. 2016) . Free from the large bacteriophage, soluble scFvs may have greater utility than their phage-bound counterparts in experiments designed for high-resolution structural characterization of their targets.
The relevance of NUsc1-targeted oligomers to AD was established in this study. This is shown by the fact that NUsc1 reacts with AbOs in both AD brain extracts and in fixed AD brain tissue but not in control brain slices or extracts. It is important to note that NUscs were initially selected for their specificities toward a synthetic preparation of AbOs (Lambert et al. 1998; Chromy et al. 2003) . The fact that NUsc1 recognizes AbOs in AD brain further strengthens previous observations that this synthetic preparation of oligomers is indeed AD-relevant (Gong et al. 2003) .
The notion that NUsc1 targets AD-relevant oligomer species is further supported by results in AD model systems. In culture, NUsc1 detected synthetic AbOs previously bound to neurons in a punctate pattern along dendrites, similar to previous observations using anti-AbO IgGs and suggesting that the AbOs targeted by NUsc1 bind synapses (Lacor et al. 2007) . In both Tg mouse and AD brain, the pattern of NUsc1 labeling is similar to the labeling obtained using full-IgG AbO antibodies to diffuse plaques, which are distinct from dense core plaques . As previously noted, this diffuse binding pattern is suggestive of NUsc1 binding to neuronal dendritic arbors (Ferreira and Klein 2011) . Furthermore, NUsc1 was found to reduce ROS accumulation in AbO-exposed cultured neurons. Here it is important to mention that although ROS production is physiological under certain levels/circumstances (e.g., Sena and Chandel 2012) , excessive ROS production is toxic to most cells, and is a toxic event implicated in the pathogenesis of AD (Perry et al. 2002) and known to be induced by AbOs . We have also demonstrated that NUsc1 completely blocked tau hyperphosphorylation induced by AbOs in cultured neurons. Taken together, these data support the notion that NUsc1 targets AD-relevant AbOs.
An interesting property of NUsc1 is its apparent specificity for a small subpopulation of AbOs. This specificity was first apparent in a previous study, in which NUsc1 was found to target a subset of AbOs that are greater than 50 kDa in molecular mass and bind to synapses in cultured neurons (Velasco et al. 2012) . Data in this study further substantiate these conclusions. In dot immunoblotting assays, NUsc1 detected a subset of AbO species detected by the full-IgG anti-AbO monoclonal antibody NU2. In an immunoprecipitation assay, only AbOs greater than 50 kDa were coprecipitated with NUsc1. Using SEC, NUsc1 was found to recognize AbO species in fractions greater, but not less than 60 kDa. This is in contrast to NU1 targeting SEC fractions of AbOs both larger and smaller than 60 kDa. Importantly, the SEC and immunoblotting assays were performed under nondenaturing conditions, crucial to allow identification of ADrelevant AbO species. Data regarding NUsc1 specificity toward oligomers of particular sizes support previously published data indicating that AbO targets of NUsc1 are larger than 50 kDa (Velasco et al. 2012) .
Altogether, we show here that the human scFv NUsc1 targets AbOs that are larger than 60 kDa in non-denaturing conditions and appear to be AD relevant, that is, they are present in AD and Tg mouse brains, bind neuronal synapses, and induce excessive ROS accumulation and tau hyperphosphorylation in neuronal culture. According to these observations, we propose that the oligomer targets of NUsc1 are a subset of 'Type I' AbOs . In addition, we predict that NUsc1 may be useful in phage-free form to isolate and stabilize this particular Type I AbO subspecies for future high-resolution structural studies, for example, cryoelectron microscopy or X-ray crystallography.
It is further possible that other NUscs, among the 11 identified in our biopanning screen, target different AbO species from NUsc1. If this turns out to be the case, those NUscs, in addition to NUsc1, would be quite valuable to characterize AbO structure-neurotoxicity relationships, as well as for differential AD diagnostics and therapeutics, given that distinct AbO species have been found to be differentially expressed in brain and CSF throughout AD progression (Bao et al. 2012; Lesne et al. 2013) . In this regard, NUscs may prove powerful diagnostic imaging probes. We recently demonstrated the diagnostic utility of our AbO-specific monoclonal antibody NU4 as an MRI (Magnetic Resonance Imaging) imaging probe in Tg mice . Further characterization of NUsc1 and NUscs2-11 is thus warranted to determine their potentials as diagnostic and therapeutic tools in AD. All experiments were conducted in compliance with the ARRIVE guidelines.
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